Clinical trial · no report yet · Phase 1/Phase 2
ARROS-1
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- NCT05118789 ↗
- Recruiting
- Nuvalent Inc.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 6 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Locally Advanced Solid Tumor; Metastatic Solid Tumor
- Interventions
- Zidesamtinib (NVL-520)
- Arms
- Phase 1 dose escalation · Experimental
- Cohort 2a · Experimental
- Cohort 2b · Experimental
- Cohort 2c · Experimental
- Cohort 2d · Experimental
- Cohort 2e · Experimental
- Enrollment
- 359 (estimated)
- Primary outcomes
- Maximum Tolerated Dose (MTD) (Phase 1)
- Recommended Phase 2 Dose (RP2D)
- Objective Response Rate (ORR) (Phase 2)
- Sponsor
- Nuvalent Inc.
- Start
- Jan 4, 2022
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05118789 · updated Sep 24, 2026